- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07673107
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Treatment of Upper Limb Essential Tremor in Adults
Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating. This study will assess if AGN-151607-DP is safe and effective by assessing adverse events and change in disease activity in adult participants with UL ET.
AGN-151607-DP is an investigational drug being developed to treat UL ET. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 94 adult participants with upper limb essential tremor will be enrolled in approximately 40 sites in the United States/Canada.
Participants will receive intramuscular injections of AGN-151607-DP or matching placebo. Duration of the study is approximately 72 weeks.
The effect of the treatment will be checked by completion of questionnaires and side effects will be monitored by medical assessments.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: ABBVIE CALL CENTER
- Telefonnummer: 844-663-3742
- E-post: abbvieclinicaltrials@abbvie.com
Studieorter
-
-
California
-
Carlsbad, California, Förenta staterna, 92011
- Rekrytering
- The Neurology Center of Southern California - Carlsbad /ID# 278194
-
Fresno, California, Förenta staterna, 93710
- Rekrytering
- Neuro Pain Research Center /ID# 277899
-
Fullerton, California, Förenta staterna, 92835
- Rekrytering
- Neurology Center Of North Orange County /ID# 278490
-
-
Connecticut
-
Stamford, Connecticut, Förenta staterna, 06905
- Rekrytering
- New England Institute for Clinical Research /ID# 277315
-
-
Florida
-
Boca Raton, Florida, Förenta staterna, 33486
- Rekrytering
- Parkinson'S Disease & Movement Disorders Center Of Boca Raton /ID# 277079
-
Orlando, Florida, Förenta staterna, 32803-1839
- Rekrytering
- Charter Research - Winter Park /ID# 277875
-
Pensacola, Florida, Förenta staterna, 32504-8649
- Rekrytering
- Emerald Coast Neurology /ID# 277898
-
-
Kansas
-
Overland Park, Kansas, Förenta staterna, 66211-1358
- Rekrytering
- Kansas Institute of Research /ID# 277068
-
-
New York
-
Amherst, New York, Förenta staterna, 14226
- Rekrytering
- Dent Neurologic Institute - Amherst /ID# 277242
-
Commack, New York, Förenta staterna, 11725
- Rekrytering
- True North Neurology /ID# 278118
-
-
North Carolina
-
Winston-Salem, North Carolina, Förenta staterna, 27103
- Rekrytering
- Neurology - Triad /ID# 277088
-
-
Ohio
-
New Albany, Ohio, Förenta staterna, 43054
- Rekrytering
- Mount Carmel Health System /ID# 278234
-
-
Tennessee
-
Memphis, Tennessee, Förenta staterna, 38157
- Rekrytering
- Veracity Neuroscience /ID# 277081
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75206-5202
- Rekrytering
- Texas Neurology /ID# 277067
-
Frisco, Texas, Förenta staterna, 75035
- Rekrytering
- Lone Star Neurology /ID# 278266
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- Houston Methodist Hospital /ID# 277326
-
-
Virginia
-
Charlottesville, Virginia, Förenta staterna, 22908
- Rekrytering
- University of Virginia /ID# 278191
-
-
Washington
-
Spokane, Washington, Förenta staterna, 99202
- Rekrytering
- Inland Northwest Research /ID# 277077
-
-
Wisconsin
-
Greenfield, Wisconsin, Förenta staterna, 53228
- Rekrytering
- Center For Neurological Disorders /ID# 277048
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3S 1N2
- Rekrytering
- True North Clinical Research /ID# 277130
-
-
Quebec
-
Lévis, Quebec, Kanada, G6W 0M5
- Rekrytering
- Centre de Recherche St-Louis /ID# 277106
-
Pointe-Claire, Quebec, Kanada, H9R 4Y2
- Rekrytering
- Genge Partners /ID# 277096
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Minimum body weight of 50 kg (110 pounds) at Screening.
-
Diagnosis of essential tremor (ET) in accordance with the modified Tremor Research Investigation Group (TRIG) criteria, as follows:
- Bilateral postural tremor with or without kinetic tremor, involving hands and forearms
- Tremor of other body parts may or may not be present in addition to upper limb (UL) tremor
- Bilateral tremor may or may not be asymmetric
- Tremor that is reported by the participant to be persistent, although the amplitude may fluctuate.
Exclusion Criteria:
- History of any medical condition that may put the participant at increased risk with exposure to purified botulinum toxin type A complex, including diagnosed muscular dystrophy (e.g., Duchenne's muscular dystrophy), myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, mitochondrial disease, or any other significant disease that might interfere with neuromuscular junctional disorders.
- History of an allergic reaction to or significant sensitivity to AGN-151607-DP or its excipients and/or other botulinum toxins.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: AGN-151607-DP
Participants will receive AGN-151607-DP. |
Intramuscular Injection |
|
Placebo-jämförare: Placebo for AGN-151607-DP
Participants will receive Placebo for AGN-151607-DP. |
Intramuscular Injection |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change From Baseline in The Essential Tremor Rating Assessment Scale (TETRAS)
Tidsram: 72 weeks
|
TETRAS assesses participants' ability to function. Items are rated on a 5-category response scale from 0 (no tremor) to 4 (severe tremor). |
72 weeks
|
|
Number of Participants with Adverse Events (AEs)
Tidsram: 72 weeks
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. |
72 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change From Baseline in The Essential Tremor Rating Assessment Scale - Upper Limb (TETRAS-UL)
Tidsram: 72 weeks
|
TETRAS Upper Limb (UL) Scale is an item of the TETRAS performance subscale that is designed to assess upper limb tremor. Items are scored from 0 to 4, with 0 indicating no tremor and 4 indicating a severe tremor. |
72 weeks
|
|
Change From Baseline in Clinical Global Impression of Severity (CGIS)
Tidsram: 72 weeks
|
CGI-S is a single item used to measure the clinician's impression of the current severity of the patient's essential tremor. The measure uses a 5-point rating scale with scores ranging none to very severe. |
72 weeks
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: ABBVIE INC., AbbVie
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- M25-850
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Tidsram för IPD-delning
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Kriterier för IPD Sharing Access
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .